240 related articles for article (PubMed ID: 38161104)
21. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
22. Physical activity and urologic cancers.
Wolin KY; Stoll C
Urol Oncol; 2012 Sep; 30(5):729-34. PubMed ID: 23021556
[TBL] [Abstract][Full Text] [Related]
23. Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers.
Seo E; Kang M
BMB Rep; 2023 Jan; 56(1):24-31. PubMed ID: 36476272
[TBL] [Abstract][Full Text] [Related]
24. Urologic Oncology Survivorship Guidelines: An Overview of the Evidence and the Current Implementation Gap.
Nguyen DD; Wallis CJD; Fleshner NE; Trinh QD; Klaassen Z; Sayyid RK
Eur Urol Focus; 2023 May; 9(3):431-434. PubMed ID: 36842920
[TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
26. Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects.
Hashemi M; Mirzaei S; Barati M; Hejazi ES; Kakavand A; Entezari M; Salimimoghadam S; Kalbasi A; Rashidi M; Taheriazam A; Sethi G
Life Sci; 2022 Nov; 309():120984. PubMed ID: 36150461
[TBL] [Abstract][Full Text] [Related]
27. Long noncoding RNA in prostate, bladder, and kidney cancer.
Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Characterization of Common and Cancer-Specific Differently Expressed lncRNAs in Urologic Cancers.
Yan YJ; Zhang L; Zhou JJ; Chen ZJ; Liao YX; Zeng JM; Shen H
Comput Math Methods Med; 2021; 2021():5515218. PubMed ID: 34335862
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant systemic therapy for urological malignancies.
Sonpavde G; Sternberg CN
BJU Int; 2010 Jul; 106(1):6-22. PubMed ID: 20553475
[TBL] [Abstract][Full Text] [Related]
30. Detection and isolation of circulating tumor cells in urologic cancers: a review.
Loberg RD; Fridman Y; Pienta BA; Keller ET; McCauley LK; Taichman RS; Pienta KJ
Neoplasia; 2004; 6(4):302-9. PubMed ID: 15256052
[TBL] [Abstract][Full Text] [Related]
31. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy indications in the treatment of metastases from urological malignancies].
Théodore C
Prog Urol; 2008 Nov; 18 Suppl 7():S219-22. PubMed ID: 19070795
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic therapy in urologic cancers: an update on clinical trials.
Faleiro I; Leão R; Binnie A; de Mello RA; Maia AT; Castelo-Branco P
Oncotarget; 2017 Feb; 8(7):12484-12500. PubMed ID: 28036257
[TBL] [Abstract][Full Text] [Related]
34. Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers.
Soma O; Hatakeyama S; Okamoto T; Fujita N; Hamano I; Tanaka T; Momota M; Yoneyama T; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Saitoh H; Nakaji S; Suzuki T; Ohyama C
Med Oncol; 2019 Sep; 36(10):88. PubMed ID: 31520152
[TBL] [Abstract][Full Text] [Related]
35. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
36. Cancer immunotherapy: new applications in urologic oncology.
Hurwitz ME; Sokhn J; Petrylak DP
Curr Opin Urol; 2016 Nov; 26(6):535-42. PubMed ID: 27584025
[TBL] [Abstract][Full Text] [Related]
37. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of serum prostate-specific antigen in urologic cancers.
Takeuchi T; Kuriyama M; Fujihiro S; Fujimoto Y; Okano M; Nishiura T
J Surg Oncol; 1983 Oct; 24(2):157-60. PubMed ID: 6195484
[TBL] [Abstract][Full Text] [Related]
39. Global Burden of Urologic Cancers, 1990-2013.
Dy GW; Gore JL; Forouzanfar MH; Naghavi M; Fitzmaurice C
Eur Urol; 2017 Mar; 71(3):437-446. PubMed ID: 28029399
[TBL] [Abstract][Full Text] [Related]
40. [Chemotherapy and radiotherapy for urological cancer].
Miyanaga N; Tsukamoto S; Hattori K; Kawai K; Shimazui T; Uchida K; Akaza H
Gan To Kagaku Ryoho; 2002 May; 29(5):709-16. PubMed ID: 12040674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
